WIRB-Copernicus Group Announces Acquisition of Alliance Biosciences - Applied Clinical Trials

ADVERTISEMENT

See our 2013 Buyers Guide Digital Edition.
WIRB-Copernicus Group Announces Acquisition of Alliance Biosciences

Source: Applied Clinical Trials

WIRB-Copernicus Group (WCG), a provider of regulatory and ethical review services for clinical research, announced that it has acquired Alliance Biosciences. Alliance Biosciences was the leading biosafety and biosecurity consulting firm in the United States and will join WCG’s biosafety division – WCG Biosafety™ – to manage the entire continuum of biosafety oversight, helping to ensure that research involving potentially hazardous agents and vectors complies with the appropriate safety and regulatory requirements from laboratory design and drug discovery through clinical testing and therapeutic application. WCG Biosafety manages more than 200 Institutional Biosafety Committees (IBCs) and has evaluated more than 140 gene transfer clinical and recombinant DNA pre-clinical research protocols to date.

 

Read the full release here.

ADVERTISEMENT

blog comments powered by Disqus

ADVERTISEMENT

Survey
As it creates a plan to implement the US biosimilar pathway, should FDA:
Borrow heavily from EMA's pathway program?
Borrow lightly from EMA's pathway program?
Create entirely its own pathway program?
Borrow heavily from EMA's pathway program?
86%
Borrow lightly from EMA's pathway program?
6%
Create entirely its own pathway program?
7%
View Results
Untitled Document
Source: Applied Clinical Trials,
Click here